RTP Mobile Logo
RTP On Demand: Current and Future Role of PARP Inhibitors in the Management of Ovarian Cancer (Audio Program)
Released January 2017

Featuring interviews with Drs Ursula A Matulonis, Thomas J Herzog and Michael Birrer. (Audio Content)

CE Disclosures and Faculty Information

    The American Cancer Society estimates that 22,280 new cases of ovarian cancer (OC) will be diagnosed in the United States in 2016 and 14,240 individuals will die of the disease. Significant resources have been invested over the past few decades in attempts to better understand the natural history of the disease, identify genetic and other factors responsible for its proliferation and develop novel therapies with the potential to significantly improve outcomes for patients. One such avenue, investigating PARP inhibition as a mechanism to combat OC development and progression, ultimately led to the 2014 FDA approval of the PARP inhibitor olaparib. Given the significant number of clinical and research questions created by this recent introduction and the rapidly expanding database surrounding PARP inhibition in general, it is clear that additional educational resources are needed to keep practicing clinicians up to date and informed. To that end, this special RTP On Demand program uses one-on-one discussion with leading investigators in the field to assist practicing clinicians with the formulation of up-to-date management strategies.


    • Use available guidelines and consensus statements to develop an evidence-based algorithm for conducting genetic screening for patients with OC.
    • Understand the rationale for the investigation of PARP inhibition as monotherapy or in combination with other novel agents for patients with BRCA mutation-positive and BRCA wild-type advanced OC, and use this information to inform protocol and nonresearch treatment options for these individuals.
    • Appreciate the recent approval of olaparib for patients with highly refractory advanced OC, and appropriately integrate this agent into the clinical management of such cases.
    • Develop an understanding of the available efficacy data and toxicity profiles of investigational PARP inhibitors to effectively prioritize clinical trial opportunities for appropriate patients with OC.
    • Educate patients about the side effects associated with approved and investigational PARP inhibitors, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity enables the participant to earn up to 2.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/RTPODOvarian116/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr MatulonisAdvisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, ImmunoGen Inc, Merck. Dr HerzogAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Pfizer Inc, Roche Laboratories Inc. Dr BirrerAdvisory Committee: Acceleron Pharma, AstraZeneca Pharmaceuticals LP, ImmunoGen Inc, Merrimack Pharmaceuticals Inc, OXiGENE Inc, Roche Laboratories Inc, Sanofi, Threshold Pharmaceuticals Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Therapeutics, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. 

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Tesaro Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: January 2017
    Expiration date: January 2018

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
RTP On Demand: Current and Future Role of PARP Inhibitors in the Management of Ovarian Cancer (Audio Program)
Released January 2017

Featuring interviews with Drs Ursula A Matulonis, Thomas J Herzog and Michael Birrer. (Audio Content)

Read print: